Ndu Adora 4

4 · ACADIA PHARMACEUTICALS INC · Filed Jun 1, 2026

AI-generated summary of this filing

Updated Jun 1, 2026

ACADIA (ACAD) Director Ndu Adora Exercises Options, Receives RSUs

What Happened

Ndu Adora, a director of ACADIA Pharmaceuticals (ACAD), reported derivative activity on May 29, 2026. The filing shows an exercise/conversion of 8,107 derivative shares and a matching disposition of 8,107 shares at $0.00, plus grants/awards of 16,004 and 9,311 restricted stock units (RSUs) — a total of 25,315 RSUs acquired/awarded. Prices shown are $0.00 or N/A; no cash value is reported in the filing.

Key Details

Transaction date: May 29, 2026; Form 4 filed June 1, 2026. The filing does not indicate a late filing.
Reported transactions:
- 8,107 shares: exercise/conversion of derivative (code M), acquired (N/A) and concurrently disposed at $0.00 (derivative).
- 16,004 RSUs: grant/award (code A), acquired at $0.00 (derivative).
- 9,311 RSUs: grant/award (code A), acquired at $0.00 (derivative).
Shares owned after transaction: not specified in the provided summary of the filing.
Footnotes of note:
- F1: Each RSU represents a contingent right to one share of common stock.
- F2: The RSUs vested in full on May 29, 2026 (the date of the annual meeting).
- F3: Option tranches (where applicable) vest quarterly over one year after grant, with final tranche earlier of one year or next annual meeting.
- F4: The RSUs will vest in full on the earlier of one year following grant or the next annual meeting.
The disposal at $0.00 is shown as a derivative disposition; such zero-dollar filings commonly reflect net settlement or shares withheld for taxes, but the filing itself does not state the reason.

Context

These transactions are primarily awards/vesting and a derivative conversion — acquisitions rather than an open-market purchase or sale. Awards and vested RSUs signal issuance/compensation events rather than an obvious market-confidence purchase by the insider.
For retail investors: awards/vesting increase insider-held equity but do not necessarily indicate the director is buying additional stock with personal funds. The filing provides share counts but no dollar values for these entries.

Form 4

Period: 2026-05-29

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-05-29+8,107→ 32,908 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-05-29−8,107→ 0 total
→ Common Stock (8,107 underlying)
Award
Director Stock Options (Right to Buy)
[F3]
2026-05-29+16,004→ 16,004 total
Exercise: $21.66Exp: 2036-05-28→ Common Stock (16,004 underlying)
Award
Restricted Stock Units
[F1][F4]
2026-05-29+9,311→ 9,311 total
→ Common Stock (9,311 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
[F2]The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
[F3]The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
[F4]The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.

Signature

/s/ Jennifer J. Rhodes, Attorney-in-Fact|2026-06-01

1 file